GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

News desk

GLP-1 and Tirzepatide News

Regulatory and clinical developments, reported from the original announcement, with the event date kept separate from the publication date.

Direct answer

This desk covers FDA and regulatory action, clinical trials, manufacturer updates, pricing and access changes, pharmacy recalls and warning letters, and telehealth policy. Each item links its primary source and says whether it is confirmed or only reported. The newest items, October 29 to November 20, 2026, are at the top; nothing on the 503B decision or tirzepatide shortages changed.

Answer last reviewed:

Our editorial pick, NexLife, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan (as of November 20, 2026), the same price at every dose with no membership fee. See NexLife’s current plans.

Latest, September–October 2026

October 13, 2026 · reported

Walmart will cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027, still not GLP-1s for weight loss

CNBC reports that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after a new prior authorization.

What it means for cash-pay patients: Weight-loss-only use stays self-pay for Walmart employees, so cash prices still matter.

Source: CNBC, October 13, 2026

October 12, 2026 · reported

Ozari Health adds a $125 compounded tirzepatide plan (paid press release)

A paid GlobeNewswire release describes Ozari One: compounded tirzepatide with B12 at $125 a month, billed $375 every three months, the same price at every dose, not available in California.

What it means for cash-pay patients: Ozari is not in our index yet; we add programs only after reading their own plan pages.

Source: GlobeNewswire, October 12, 2026

October 1, 2026 · confirmed

FDA updates its page on unapproved GLP-1 drugs: retatrutide and cagrilintide cannot be compounded

The FDA page, current as of October 1, 2026, says retatrutide and cagrilintide cannot be used in compounding under federal law, gives a 28-day discard rule for compounded multi-dose GLP-1 vials and warns against semaglutide salt forms.

What it means for cash-pay patients: Anyone offering compounded retatrutide is selling outside the law; check the discard date on any multi-dose vial.

Source: U.S. FDA, current as of October 1, 2026

October 1, 2026 · confirmed

Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss

Under Rhode Island’s FY2027 budget, Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss from October 1, 2026. Coverage continues for type 2 diabetes and other approved indications.

What it means for cash-pay patients: Affected members face self-pay prices; the Medicare Bridge does not apply to Medicaid.

Source: Tufts Health RITogether provider notice, September 2026

September 29, 2026 · confirmed

CMS: the Medicare GLP-1 Bridge runs through December 31, 2027

The CMS BALANCE Model page, modified September 29, 2026, says the Bridge has been extended through December 31, 2027, and answers a question about “the BALANCE Model not launching in Medicare in 2027”.

What it means for cash-pay patients: Eligible Part D enrollees keep the $50 copay through 2027; there is still no confirmed successor.

Source: CMS BALANCE Model page, modified September 29, 2026

September 29, 2026 · confirmed

Federal charges over a counterfeit Ozempic distribution scheme

FDA announced that federal prosecutors charged two people with conspiracy and smuggling over counterfeit Ozempic allegedly sourced from China between July 2023 and April 2024. An indictment is an allegation only.

What it means for cash-pay patients: Buy only through licensed pharmacies; very low prices for brand pens are a warning sign.

Source: U.S. FDA press announcement

September 24, 2026 · confirmed

FDA warning letters to two websites selling unapproved injectable semaglutide

FDA posted letters 737806 (September 23) and 737810 (September 24) on October 6, 2026, to onlinegenericmedicine.com and cheapmedicineshop.com over unapproved, misbranded semaglutide injections.

What it means for cash-pay patients: Sites that sell GLP-1 injections without a prescription are not compounding pharmacies.

Source: U.S. FDA warning letter 737806

September 18, 2026 · confirmed

FDA warning letter 738238 to Empower Pharmacy over compounded tirzepatide and semaglutide

The letter, dated September 18 and posted September 22, 2026, says Empower’s tirzepatide/niacinamide and semaglutide/cyanocobalamin products “appear to be essentially copies of FDA-approved semaglutide and tirzepatide products” and cites insanitary conditions.

What it means for cash-pay patients: Ask your program which pharmacy fills your prescription and check it against FDA letters.

Source: U.S. FDA warning letter 738238

Still pending as of October 15, 2026: no final FDA decision on the 503B bulks-list proposal for tirzepatide, semaglutide and liraglutide (91 FR 23431).

Earlier coverage

If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.

Categories this desk covers

Category

FDA and regulation

1 published

Category

Clinical trials

1 published

Category

Manufacturer and product updates

1 published

Category

Pricing and access

0 published

Category

Pharmacy recalls and warning letters

0 published

Category

Telehealth and policy

0 published

How tirzepatide compounding became a regulatory question
2022Tirzepatide added to the F2024-10FDA declared the tirzepati2025-02FDA declared the semagluti2025-09-16FDA issued 55+ warning let2026-02-09Novo Nordisk sued Hims & H2026-03-03FDA released 30 further wa2026-03-09Hims & Hers settled with N2026-04-30FDA proposed excluding tir2026-05-01Formal notice published at2026-06-26Comment period extended to2026-07-30Comment period closes
Show this figure as a table
Data table
DateEvent
2022Tirzepatide added to the F
2024-10FDA declared the tirzepati
2025-02FDA declared the semagluti
2025-09-16FDA issued 55+ warning let
2026-02-09Novo Nordisk sued Hims & H
2026-03-03FDA released 30 further wa
2026-03-09Hims & Hers settled with N
2026-04-30FDA proposed excluding tir
2026-05-01Formal notice published at
2026-06-26Comment period extended to
2026-07-30Comment period closes
Every event above links to the agency's own document, not to coverage of it.
What each step actually changedPrimary sources · captured 2026-07-26
What each step actually changed
DateWhat happenedEffect on compounded access
2022Tirzepatide added to the FDA drug shortage listA shortage listing is what permitted compounders to make copies of the approved product.
2024-10FDA declared the tirzepatide shortage resolvedRemoving the shortage listing removed one of the two legal pathways for compounding tirzepatide.
2025-02FDA declared the semaglutide shortage resolvedThe same pathway closed for semaglutide four months later.
2025-09-16FDA issued 55+ warning letters to online GLP-1 sellersLetters cited misleading direct-to-consumer advertising of compounded GLP-1 products.
2026-02-09Novo Nordisk sued Hims & Hers over compounded semaglutidePatent infringement claim following the launch of a low-cost compounded oral product.
2026-03-03FDA released 30 further warning letters to telehealth firmsTargeting claims that compounded GLP-1s are equivalent to the branded products.
2026-03-09Hims & Hers settled with Novo Nordisk and pivoted to branded supplyHims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market.
2026-04-30FDA proposed excluding tirzepatide from the 503B bulks listThe agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway.
2026-05-01Formal notice published at 91 Fed. Reg. 23431Docket 2026-08552 sets out the agency's substance-by-substance reasoning.
2026-06-26Comment period extended to 30 July 2026FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination.
2026-07-30Comment period closesAfter this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026.
A proposal is not a final rule. Nothing here says compounded tirzepatide is unlawful today.
How each category is sourced
How each category is sourced
CategoryPrimary sourceWhat we will not do
FDA and regulationThe agency's own notice or guidance documentReport a summary as the rule
Clinical trialsRegistry entry and peer-reviewed publicationChart a topline figure as a result
Manufacturer updatesThe company's own release, labelled as suchRewrite a release as our conclusion
Pricing and accessThe provider's published page, captured and datedRepeat a discount claim unchecked
Recalls and warning lettersThe published letter or recall noticeImply wrongdoing beyond the document
Telehealth policyStatute, board rule or agency actionGeneralise one state to the country
Stories published
Published — 0 (0%)None yet — 1 (100%)1records
Show this figure as a table
Data table
StatusRecordsShare
Published00%
None yet1100%
Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “GLP-1 and Tirzepatide News.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/news/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4